Giuseppe Caruso, Gynecology Oncology Specialist at European Institute of Oncology, shared a post a post on LinkedIn:
“This is great news – an additional opportunity – for our platinum-resistant recurrent ovarian cancer (PRROC) patients.
Following FDA, EMA also approved pembrolizumab (Keytruda) in combination with paclitaxel, with or without bevacizumab, for PRROC patients whose tumors express PD-L1 with a CPS ≥ 1 and who have received 1-2 prior systemic treatment regimens.
The future in GynOnc looks brighter every day!”
Other articles about EMA on OncoDaily.